Gefitinib or erlotinib as maintenance therapy in patients with advanced stage non-small cell lung cancer: a systematic review - Test2 - elhamkhani - TriplyDB

Gefitinib or erlotinib as maintenance therapy in patients with advanced stage non-small cell lung cancer: a systematic review

Gefitinib or erlotinib as maintenance therapy in patients with advanced stage non-small cell lung cancer: a systematic review

http://www.wikidata.org/entity/Q27023100

about

Icotinib is an active treatment of non-small-cell lung cancer: a retrospective study Maintenance therapy for advanced non-small cell lung cancer (NSCLC)Metastatic pancreatic cancer: Is there a light at the end of the tunnel?Ovine pulmonary adenocarcinoma: a large animal model for human lung cancer Protein kinase inhibitors in metastatic colorectal cancer. Let's pick patients, tumors, and kinase inhibitors to piece the puzzle together!The Efficacy of Brucea javanica Oil Emulsion Injection as Adjunctive Therapy for Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis.Effective ultra-low doses of erlotinib in patients with EGFR sensitising mutation Sequential treatment of icotinib after first-line pemetrexed in advanced lung adenocarcinoma with unknown EGFR gene status.A checklist designed to aid consistency and reproducibility of GRADE assessments: development and pilot validation.Expression of IRAK1 in lung cancer tissues and its clinicopathological significance: a microarray study.Ginkgo biloba extract decreases non-small cell lung cancer cell migration by downregulating metastasis-associated factor heat-shock protein 27.Prognostic implications of ezrin and phosphorylated ezrin expression in non-small cell lung cancer The efficacy and safety of EGFR inhibitor monotherapy in non-small cell lung cancer: a systematic review.Gefitinib in non-small-cell lung cancer-an old lesson new re-visited Gefitinib and erlotinib in metastatic non-small cell lung cancer: a meta-analysis of toxicity and efficacy of randomized clinical trials.NQO1 protein expression predicts poor prognosis of non-small cell lung cancers Heat shock protein 27 promotes cell proliferation through activator protein-1 in lung cancer.Erlotinib Pretreatment Improves Photodynamic Therapy of Non-Small Cell Lung Carcinoma Xenografts via Multiple Mechanisms.The Effect of ShenQi FuZheng Injection in Combination with Chemotherapy versus Chemotherapy Alone on the Improvement of Efficacy and Immune Function in Patients with Advanced Non-Small Cell Lung Cancer: A Meta-Analysis.Unexpected responses to EGFR inhibition in NSCLC.Biopsy testing in an inoperable, non-small cell lung cancer population-a retrospective, real-life study in Sweden The effect of ribosomal protein S15a in lung adenocarcinoma.Increasing the α 2, 6 sialylation of glycoproteins may contribute to metastatic spread and therapeutic resistance in colorectal cancer.PET/CT in therapy evaluation of patients with lung cancer.Class act: safety comparison of approved tyrosine kinase inhibitors for non-small-cell lung carcinoma.Epidermal Growth Factor Receptor Inhibition in the Management of Squamous Cell Carcinoma of the Lung.Hidden treasures in "ancient" microarrays: gene-expression portrays biology and potential resistance pathways of major lung cancer subtypes and normal tissue.Inhibition of microRNA-196a might reverse cisplatin resistance of A549/DDP non-small-cell lung cancer cell line.High cofilin-1 levels correlate with cisplatin resistance in lung adenocarcinomas.Presence of pleural effusion is associated with a poor prognosis in patients with epidermal growth factor receptor-mutated lung cancer receiving tyrosine kinase inhibitors as first-line treatment.Association between downexpression of MiR-203 and poor prognosis in non-small cell lung cancer patients.Epidermal growth factor receptor-tyrosine kinase inhibitors in advanced squamous cell carcinoma of the lung: a meta-analysis.Development and validation of a UPLC-MS/MS assay for the quantification of simotinib in human plasma.

P2860

Q21132047-B0DD202C-0AB7-48E3-BE6D-B498049B675E Q24186793-16F701E7-3FEA-47DA-81B0-566DF55EBEC6 Q28082919-B6490CC5-AE85-4F4D-8DD8-5EAD9CCFD68C Q28088774-25CD9F90-5BDD-4EC1-B7F9-9811D1A49BD7 Q33356339-3FA0E209-80A5-49AD-9FF6-193817E42720 Q33438129-D4CC8C90-BDA6-497E-BBBD-B3F90DF661A4 Q33955857-EEAD1F9D-7737-4A06-A422-770627D42E41 Q33995172-E9E1C215-AABC-430B-9977-340320C97937 Q34013434-EA852B00-C765-47F0-A5AB-2F7292A127D8 Q34733257-81DF1619-4C06-4CDE-82C3-B0803AE539E5 Q35117661-CC298C60-0B6D-47EE-AC2F-43FA7E2F72AD Q35120842-DF11E0F9-A0FC-4D61-9F62-50375866B04E Q35164824-DE186215-DF8F-429B-BAA3-C50796EBF22C Q35200450-C42FC03C-EBF2-43D0-919B-4F9D8F64F07A Q35345489-620BCB09-683A-4434-8A1A-6F7D55E5B813 Q35409789-AFB1AC62-F928-4662-8BE8-5DA25D85799D Q35758521-1FC29DD7-AC85-4EED-BE00-59FE0D0E744A Q35920966-C4112646-DFC8-4090-9623-8D79D60CEBB8 Q35970561-F87068E6-5B64-40E8-B020-7DD047689F95 Q36378879-B27A163C-FF7C-4D6E-BC21-0AD182FC1161 Q36437538-72F6A262-39D2-4E06-937D-6D9DA94303C4 Q36691277-600E181B-DF44-41AD-8D57-C8FC16B39461 Q38169157-209BE2DD-6C4D-4482-BA16-D8C46E69B36E Q38202189-4FF11C52-0BE1-4ED3-A979-EBA90AC70CAA Q38262804-67882F82-4F90-4C6C-9138-6ABA52E10202 Q38289406-E285D692-2FAB-47CA-9669-E1BC25884643 Q38471484-B7B092D0-D921-4DB2-BE95-72D251AC8220 Q38834921-DC30662B-9892-40B2-8CEC-8017B5D2664D Q39098144-CC236FD1-14F0-4020-A5C1-5945629380E9 Q51168062-00371E8D-AF0F-4855-AB61-DE0EAA4F1EA1 Q53367071-52F5FFAA-5208-44C6-92B1-07BB80EC9813 Q54329048-0F5AFF3E-19FE-4037-A566-2C7E6B7BE6EA Q54385410-25894997-A0A4-4B06-ADF6-A0C18DB1537F

P2860

Gefitinib or erlotinib as maintenance therapy in patients with advanced stage non-small cell lung cancer: a systematic review

http://www.wikidata.org/entity/Q27023100

description

2013 nî lūn-bûn

@nan

2013 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի մարտին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Gefitinib or erlotinib as main ...... ng cancer: a systematic review

@ast

Gefitinib or erlotinib as main ...... ng cancer: a systematic review

@en

Gefitinib or erlotinib as main ...... ng cancer: a systematic review

@nl

type

label

Gefitinib or erlotinib as main ...... ng cancer: a systematic review

@ast

Gefitinib or erlotinib as main ...... ng cancer: a systematic review

@en

Gefitinib or erlotinib as main ...... ng cancer: a systematic review

@nl

prefLabel

Gefitinib or erlotinib as main ...... ng cancer: a systematic review

@ast

Gefitinib or erlotinib as main ...... ng cancer: a systematic review

@en

Gefitinib or erlotinib as main ...... ng cancer: a systematic review

@nl

P1433

Q27023100-581C790E-5BD8-4A6A-AE31-57F2BEB35066

P1476

Q27023100-069644F1-B6A5-4AC9-8D29-5DA10631159A

P2093

Q27023100-00F70318-D154-476F-B557-7836801DD5A2

Q27023100-25652D2B-1CF5-43E0-807E-FEC840D94346

Q27023100-7BF62639-8A68-4F39-B0A7-D13592503158

Q27023100-9CDA31E2-2B42-44FE-BFB6-4BD13C9E647C

Q27023100-A17F0E8F-E6C2-4B07-A4D6-14EB9E747616

Q27023100-E95EB25D-89C2-4279-9A83-0B0EA0BFF591

Q27023100-EC593DF7-09D9-46C7-BB14-57A8109452F7

P275

Q27023100-C19372E3-80EB-4CC5-90E1-83D5D95C3959

P2860

Q27023100-144D7C39-1473-43ED-BA44-98758897555C

Q27023100-1971CB19-8CCE-46D8-9108-53C02D7B4494

Q27023100-1A4643CB-B596-4E61-932F-E6028F74F9D7

Q27023100-1C74BA44-2546-4210-A065-3F70119B6D99

Q27023100-1D20BDF9-6F24-46D9-B148-BCB65321C908

Q27023100-26EF0288-3C33-4F8A-B5B2-5D858E087DC1

Q27023100-3078E4F8-D5F0-435B-BA6A-65EE52D611E6

Q27023100-4B0737F8-BA56-4B37-809C-BCDA18CB5D1C

Q27023100-5CE0038F-FF4E-4DAC-83FF-A775BA0307F2

Q27023100-64B597AC-EE0F-4413-B3DF-2747D0917A1B

P304

Q27023100-E96A55CA-03D7-4139-8D2A-252D8C4A1B1A

P31

Q27023100-04C5AE45-CD41-48C0-B757-EA8147792795

Q27023100-04F26422-FC42-4569-BD43-969730909622

Q27023100-B377789E-C697-4383-AFE9-F37197B7E6CB

P3181

Q27023100-D68068A1-42EA-4A98-94B4-D661CC407E21

P356

Q27023100-2CC55E7F-1DB8-4448-B580-F7C6391D5F7E

P407

Q27023100-E1A78257-A2EA-4C67-A232-19F9F2465E1A

P433

Q27023100-E08DC1F8-622B-465C-B230-802B75E88960

P478

Q27023100-8DDE1725-92CE-44CF-8D34-798B5A29FCD0

P50

Q27023100-A1A49A04-922D-495A-948B-295AFD220FEF

P5008

Q27023100-09126FC2-AAAD-4F3E-B891-98FF3B7E0C65

P577

Q27023100-E1F54CC6-3BE5-4733-8274-EC5F0860955D

Q27023100-FBFC6280-417B-4176-831C-BCF9B5F50D02

P5875

Q27023100-24EF12C3-A411-4473-807C-AE90051D8493

P698

Q27023100-9E18B601-ECF2-4B77-B9AE-28C34C0C7BC5

P921

Q27023100-1E1B3AF3-FA01-4A9C-8D6C-8DA8F9F26E25

Q27023100-5CF73AA2-ED6F-483A-8386-A6FEB66146F8

Q27023100-7CFCC311-9AB7-4ACB-B1C8-C52DF1C24507

Q27023100-88BBF577-9B5E-40A4-963E-67A4B145F678

Q27023100-AA175391-FCA7-400D-A1F5-CAA390AEC2D8

Q27023100-F93BCCA3-AC0A-4F6A-8500-60732A4BC2C7

P932

Q27023100-DAE1F2AF-D82C-41B8-9F70-66DF77ADD4EB

P3181

P356

JOURNAL.PONE.0059314

P1433

P1476

Gefitinib or erlotinib as main ...... ng cancer: a systematic review

@en

P2093

Lingjun Zhu

http://www.w3.org/2001/XMLSchema#string

Renhua Guo

http://www.w3.org/2001/XMLSchema#string

Xiaofeng Chen

http://www.w3.org/2001/XMLSchema#string

Yingying Qian

http://www.w3.org/2001/XMLSchema#string

Yiqian Liu

http://www.w3.org/2001/XMLSchema#string

Yongmei Yin

http://www.w3.org/2001/XMLSchema#string

Yongqian Shu

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 4.0 International

P2860

2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

Erlotinib in previously treated non-small-cell lung cancer

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

Single agent maintenance therapy for advanced stage non-small cell lung cancer: a meta-analysis

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

Scales to assess the quality of randomized controlled trials: a systematic review.

Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil.

P304

e59314

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

systematic review

P3181

5056072

http://www.w3.org/2001/XMLSchema#string

P356

10.1371/JOURNAL.PONE.0059314

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P50

Oluf Dimitri Røe

P5008

P577

2013-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

2013-03-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236106508

http://www.w3.org/2001/XMLSchema#string

P698

23555654

http://www.w3.org/2001/XMLSchema#string

P921

heterocyclic compound

mechanism of action

non-small-cell lung carcinoma

P932

3605444

http://www.w3.org/2001/XMLSchema#string